Abstract Identification and characterization of the genetic background in patients with the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome is important since control programmes can in a costeffective manner prevent cancer development in high-risk individuals. HNPCC is caused by germline mismatch repair (MMR) gene mutations and the genetic analysis of HNPCC therefore includes assessment of microsatellite instability (MSI) and immunohistochemical MMR protein expression in the tumor tissue. MSI is found in >95% of the HNPCC-associated tumors and immunostaining using antibodies against the MMR proteins MLH1, MSH2, and MSH6 has been found to correctly pinpoint the affected gene in about 90% of the cases. The PMS2 antibody was the most recently developed and we have in a clinical material assessed the added value of PMS2 immunostaining in 213 patients with suspected hereditary colorectal cancer. All 119 MSS tumors showed retained expression for all four antibodies and PMS2 did thus not identify any underlying MMR defect in these cases. However, PMS2 immunostaining contributed to the characterization of the MMR defect in a subset of the MSI tumors. Concomitant loss of MLH1 and PMS2, which functionally interact in the MutLa complex, was found in 98% of the tumors from patients with germline MLH1 mutations. Among the 12 MSI-high tumors with retained expression of MLH1, MSH2 and MSH6, 8 tumors showed loss of PMS2 staining, and mutations in MLH1 were identified in 2 and mutations in PMS2 in 3 of these individuals. In summary, isolated loss of PMS2 was found in 8% of the MSI-high tumors in our series, including 8/12 previously unexplained MSI-high tumors, in which mutations either in MLH1 or in PMS2 were identified in five cases.
Introduction
Mutation carriers in families with hereditary nonpolyposis colorectal cancer (HNPCC) have a 90% lifetime risk of developing cancer unless control programmes aimed at early tumor detection are initiated. The highest risks apply to colorectal cancer (70-80%) and endometrial cancer (40-60%) and 1/3 of the individuals will develop a second primary cancer [1, 2] . Germline mutations in the mismatch repair (MMR) genes MSH2 and MLH1 were in 1993-1994 found to be the major cause of HNPCC and later MSH6 mutations were identified in a smaller subset of the patients [3] [4] [5] [6] . The number of HNPCC families in which the underlying genetic alteration has been identified has gradually increased because of possibilities of pinpointing the affected gene by immunostaining, recognition of disease-causing mutations in MSH6, and refined methods for mutation analysis, including screening for large, intragenic MMR gene rearrangements, such as deletions and insertions. Currently, the HNPCC-causing mutations are estimated to affect MLH1 in 50% of the families, MSH2 in 39%, MSH6 in 7%, and PMS2 in occasional families [7] . The PMS2 gene has been associated with development of hereditary cancer in a small number of families, but although most of the mutations identified have been deleterious, PMS2 rarely seems to predispose to autosomal dominant inheritance and its possible causative role in HNPCC still needs to be clarified [8] [9] [10] [11] .
Assessment of the MMR status is the first step in the clinical evaluation of families with suspected HNPCC. Analysis of microsatellite instability (MSI) has traditionally been used and a MSI-high phenotype is found in > 95% of HNPCC-tumors [12] . Immunohistochemical staining using antibodies against the MMR-proteins MLH1, MSH2, and MSH6 has been reported to detect 90% of the MMR-defective tumors and has been introduced as a quick and cheap screening methods that also has the advantage of pinpointing the gene that should be subjected to mutation analysis [13] [14] [15] [16] [17] [18] . The MMR proteins functionally interact through dimerization in the MutSa (MSH2-MSH6) and MutLa (MLH1-PMS2) complex [19] . Mutations affecting the major HNPCC-associated genes, MLH1 and MSH2, do in most cases lead to degradation of the heterodimerizing protein partner and thus cause concurrent immunohistochemical loss of MSH6 and PMS2, respectively. In contrast, germline mutations that affect MSH6 or PMS2 result in tumors that in most cases show immunohistochemical loss of only the mutant MMR protein.
The monoclonal antibody against PMS2 was the most recently developed MMR protein antibody. Because of the interactions between MLH1 and PMS2 a possible added value from PMS2 immunostaining in the diagnosis of HNPCC may be related both to its role as a dimerization partner to MLH1 and to mutations in PMS2 [7] . We therefore, aimed to evaluate the added value of immunostaining for PMS2 in the genetic analysis of individuals with suspected HNPCC.
Materials and methods

Patients
Individuals who seeked genetic counselling because of suspected hereditary colorectal cancer at the oncogenetic clinics at the University Hospital in Lund and at the Karolinska University Hospital in Stockholm were included in the study and had given informed consent for the genetic analysis. The study includes colorectal cancers from 213 individuals, all of which were selected for HNPCC analysis based on the Bethesda guidelines [20] . The different subgroups consisted of patients classified as HNPCC (n = 85) according to the revised Amsterdam criteria [21] , familial CRC (n = 86) defined as at least two first-degree relatives with hereditary with CRC, individuals with metachronous CRC and endometrial cancer (n = 6), and individuals with CRC at young age (n = 36), defined as a colorectal cancer below age 50. Tumor blocks with at least 30% viable tumor tissue were selected for the study. MSI analysis had previously been performed and identified 119 microsatellite stable (MSS) tumors, four unclassified tumors (although affected family members had developed MSS cancers), and 90 MSI-high tumors.
Immunohistochemistry
Immunostaining was performed on fresh 4-lm sections from formalin-fixed, paraffin-embedded tissue blocks. The sections were mounted on DakoCytomation ChemMate Capillary Gap Microscope slides (DakoCytomation, Glostrup, Denmark) and dried at room temperature overnight followed by incubation at 60°C for 1-2 h. The tissue sections were deparaffinized in xylol and rehydrated through descending concentrations of ethanol. Antigen retrieval was achieved by microwave treatment in TE-buffer (10 mM Tris, 1 mM EDTA), pH 9.0, at 800 W for 8 min followed by 15 min at 300 W. The slides were then allowed to cool for at least 20 min in the TE-buffer solution. IHC staining was performed in an automated immunostainer (TechMate 500 Plus, DakoCytomation) according to the manufacturer's instructions. The antibodies and dilutions were as follows: mouse monoclonal IgG antibodies to MLH1 (clone G168-15, dilution 1:100; BD PharMingen, San Diego, CA, USA), MSH2 (clone FE-11, dilution 1:100; Oncogene Research Products, San Diego, CA, USA), MSH6 (clone 44, dilution 1:1000; BD Transduction Laboratories, Lexington, KY, USA), and PMS2 (clone A16-4, dilution1:500, BD PharMingen). For MLH1 and MSH2 we initially used the LSAB TM (labelled streptavidin biotin) detection kit (DakoCytomation), but after 150 tumors changed the staining protocol to be based on the EnVision TM detection kit (DakoCytomation) with an extra enhancing step. The EnVision TM detection kit was also used for all stainings of MSH6 and PMS2. After incubation with the primary antibody rabbit anti-mouse immunoglobulins (DakoCytomation, dilution 1:400) were applied to the sections and they were incubated for 20 min. All tissue sections were counterstained with hematoxylin for 1 min, rinsed in running tap water for 10 min, dehydrated in ascending concentrations of alcohol and mounted. Evaluation was performed independently by two of the authors (M.N. and B.H.). A positive staining was defined as an unequivocal nuclear staining in the neoplastic cells, and nuclear staining was required in the stromal components of the tumor. Loss of expression was defined as a tumor cell population without nuclear staining in the presence of staining in normal epithelial, stromal, or inflammatory cells or within infiltrating lymphoid cells ( Figs. 1 and 2 ). MSI analysis and mutation analysis were not within the scope of this study, but standard methods for the MSI analysis were used and the classification of into MSI-low, MSI-high or MSS was according to the NIH guidelines [12] . Mutation screening was performed for the gene corresponding to the MMR protein loss primarily by sequencing of all exons including the intron-exon boundaries. The primer sequences and the PCR conditions are available from the authors upon request. Additional analysis with the multiplex ligation-dependent probe amplification (MLPA) was performed in cases where no mutation had been identified by sequencing. MLPA allows detection of large intragenic rearrangements and the SALSA MLPA kit P003 MLH1/MSH2 (MRC-Holland, Amsterdam, the Netherlands) was used according to the manufactureŕs instructions. In short, MLPA is based on the ligation of oligonucleotides adjacent to the target sequence. The different probe lengths allow performing a multiplex PCR, and analysis thereof in an ABI PRISM Genetic Analyzer and comparison to the control sample included (for details see www.mlpa.com). Details on this analysis are available from the authors upon request. Mutation analysis of PMS2 was performed using long PCR and the technique as well as the identification of mutations has been described elsewhere [22] .
Results
All the 119 MSS tumors (of which 62 were clinically classified as HCRC, 23 as HNPCC, 31 were derived from young individuals, and 3 were included because of metachronous colorectal and endometrial cancer) showed retained expression for all 4 antibodies. Also the 21 tumors (20 of which belonged to HNPCC families) from individuals whose tumors showed immunohistochemical loss of MSH2 and/or MSH6 showed retained immunostaining for PMS2. Loss of MLH1 was identified in 61 tumors (from 35 HNPCCfamilies, 20 individuals with HCRC, 3 young patients, and 3 individuals with metachronous cancer) and 60 of these tumors showed concomitant loss of PMS2. The remaining tumor with retained PMS2 staining was derived from a patient with a nonsense mutation in MLH1, exon 19 (c.2141G>A, p.W714X). Hence, PMS2 staining identified 98% of the MLH1 mutant tumors in our series. Of the 12 MSI-high tumors with retained expression of MLH1, MSH2, and MSH6, 8 showed loss of expression for PMS2 only (Figs. 1 and 2 ). These individuals were subjected to mutation analysis using MLPA for MLH1 and long PCR for the analysis of PMS2, the latter has been reported in [22] . Among these, two individuals were by MLPA found to carry a deletion of exons 14-19 of MLH1 (Fig. 2c) , and three individuals were found to carry mutations in PMS2 [22] , whereas no mutation has been identified in the remaining three cases (Table 1) .
Discussion
HNPCC is estimated to cause about 2% of colorectal cancer [23, 24] . Identification of cases with suspected heredity and characterization of disease-causing mutations in HNPCC-families is important since it allows inclusion of high-risk individuals into control programmes [25] . Identification of the disease-causing mutations with possibilities for predicitive genetic testing is also requested by most family members, and although often experienced as stressful, has been demonstrated to be psychologically beneficial for most individuals and colonoscopic controls recommended have proven cost-effective [26] [27] [28] . The introduction of immunostaining has facilitated the genetic analysis since a subset of the families can be selected for further mutation analysis of a specified MMR gene based on the results from the immunohistochemical analysis only. Several studies that have applied immunostaining for MLH1, MSH2, and MSH6 in the diagnosis of HNPCC have demonstrated that 5-10% of the MSI-high tumors show retained staining for all three proteins [14, 17, 29, 30] . This subset of tumors is probably heterogenous and several reasons may apply; weak or non-evaluable immunostainings because e.g., suboptimal fixation with lack of positive internal control, mutations that escape detection, and MMR defects due to mutations in not yet identified MMR genes [31, 32] . However, identification of the genetic background to the MMR defect in these tumors would be clinically valuable. When immunostaining for PMS2 was added in our series, 8/12 MSI-high tumors showed isolated loss of PMS2. Overall, loss of PMS2 only occurred in 8% of the MSI tumors, which is in line with the results from previous studies in which 3-11% of the MSI-high tumors have shown loss of PMS2 only [15-17, 29, 30, 33] . Since immunostaining for MLH1 tends to show the greatest variability in the quality of staining and since missense mutations in MLH1 may be associated with retained protein expression, we have previously sequenced the entire MLH1 gene in patients with MSIhigh tumors that show retained expression of MLH1, MSH2, and MSH6, but no mutation was identified in these cases. The loss of loss of PMS2 immunostaining in eight cases in our series led to supplementary analysis using the MLPA assay, which revealed a deletion of exons 14-19 in MLH1 in two patients, who were later found to be related (Fig. 2, Table 1 ). Hence, the MLH1 antibody used recognized the truncated variant containing exons 1-13, but the resultant loss of PMS2 function allowed identification of a large deletion that had escaped detection in the previous mutation analysis. Identification of a exon 15 deletion in MLH1 has also previously been described in a patient with isolated loss of PMS2 staining [34] . Concordant loss of PMS2 staining was found in 98% of the MLH1 defective tumors and the discordant tumor identified herein was a colon carcinoma derived from a patient with a nonsense mutation at the 3¢ end of MLH1. Occasional such tumors have been described also in other studies, which suggest that degradation of PMS2 is not complete in all HNPCC-associated tumors with mutations in MLH1 [15, 32] .
Loss of PMS2 was found in 8/12 MSI tumors that had retained immunostaining for MLH1, MSH2, and MSH6 and we conclude that addition of PMS2 immunostaining provides valuable information on the cause of the MMR defect since it allowed identification of mutations in five of these cases; two had an intragenic deletion in MLH1, which demonstrated the value of performing MLPA in selected cases, and three had mutations in PMS2, albeit with yet unclear pathogenicity [22] . Immunostaining using all four antibodies, which allows determination of the expression of the protein partners MLH1-PMS2 and MSH2-MSH6, is likely to identify MMR defective tumors with a sensitivity as high as 95% and thus has a sensitivity similar to the more complex MSI analysis. The observation of isolated loss of PMS2 staining in 3-11% (in this study 8%) of the MSI-high tumors suggests that the role of PMS2 in the development of MMR-defective tumors may be larger than previously recognized, although its role as a causative event in HNPCC-development remains to be elucidated. 
